Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-253-7
CAS number: 104-93-8
4-methylanisol has a
molecular weight of 122 g/mol and is present as a liquid with a low
volatility (0.1 kPa at 17 °C). It is moderately lipophilic with a logPow
of 2.8 and shows a low water solubility.
Based on the oral
acute and repeated dose studies, systemic availability 4-methylanisol is
expected after oral or inhalative exposition, although the low
volatility of 4-methylanisol does not imply the inhalation to be a
relevant route of exposure.
Mortality in rats has
been reported after single oral administration via gavage using corn oil
as vehicle (RIFM1971) and single oral application in mice resulted in
mortality, clinical and necropsy findings (Givaundan MT1971).
Administration of 4-methylanisol in olive oil for 4 weeks to Wistar rats
via gavage resulted in changes of clinical chemical parameters and
adverse liver effects (Key.BASF21C0810/89101). Evidences for systemic
availability via the oral route can further be derived from the general
systemic and developmental toxicity observed
in an oral reproduction/ developmental toxicity screening test in rats
potential of 4-methylanisol to penetrate through skin, a dermal
absorption study is available as short summary from a secondary source
(Hawkins 1993). Groups of 4 male Sprague-Dawley rats were treated
topically (occlusive) with a single doss of (14)C-4-methylanisole (100,
320, 1000 mg/kg bw in diethyl phthalate) for 6 hours. After 72 hours,
total urinary excretion accounted for about 12% dose in rats dosed at
100 & 320 mg/kg and about 20% dose in rats dosed at ca. 1000 mg/kg.
Total excretion in faeces accounted for 0.05-0.17% of the applied dose
at all dose levels. Radioactivity in expired air accounted for about 11,
23 & 37 for 100,
320 and 1000 mg/kg bw respectively. Overall, the bioavailability via
dermal route can be estimated to be approx. 23%, 35%, 57% of the applied
dose (100, 320 and 1000 mg/kg bw respectively).
Based on its molecular
weight and moderate lipophilicity, a certain cellular uptake in eg.
adipose tissues is expected. Distribution into the liver is assumed
based on the adverse effects seen in the oral repeated dose study.
metabolisation for aromatic ethers, one or more of three pathways, i.e.
ring hydroxylation, O-dealkylation, or side-chain oxidation would be
expected followed by a conjugation with glucuronic acid, sulfate or
glycine. After a single oral dose of 4-methylanisole to rabbits, anisic
acid (mainly as ester glucuronide and anisuric acid) and p-cresol was
excreted in the urine (Bray 1955).
Based on its log Po/w, low water solubility
and the evident excretion after dermal application , bioaccumulation of
4-methylanisol is considered to be unlikely.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again